DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis

Nature Communications

Volumn 8, Issue , 2017, Pages

  Mor Vaknin, Nirit ^a   Saha, Anjan ^a,b   Legendre, Maureen ^a   Carmona Rivera, Carmelo ^c   Amin, M Asif ^a   Rabquer, Bradley J ^a,d   Gonzales Hernandez, Marta J ^a,e   Jorns, Julie ^a   Mohan, Smriti ^b   Yalavarthi, Srilakshmi ^a   Pai, Dave A ^a,f   Angevine, Kristine ^a,g   Almburg, Shelley J ^b   Knight, Jason S ^a   Adams, Barbara S ^a   Koch, Alisa E ^a   Fox, David A ^a   Engelke, David R ^a   Kaplan, Mariana J ^c   Markovitz, David M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^d ALBION COLLEGE   (United States)

^e Rubicon Genomics Inc   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g Appistry Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; DNA; PROTEIN; PROTEIN DEK; UNCLASSIFIED DRUG; CHEMOTACTIC FACTOR; DEK PROTEIN, HUMAN; DEK PROTEIN, MOUSE; DNA BINDING PROTEIN; NONHISTONE PROTEIN; ONCOPROTEIN; POLY ADP RIBOSE BINDING PROTEIN; ZYMOSAN;

DNA; JUVENILE; PROTEIN; RNA; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMATIN; CONTROLLED STUDY; EXPERIMENTAL MODEL; EXTRACELLULAR TRAP; FEMALE; IN VIVO STUDY; MALE; MOUSE; NEUTROPHIL; NONHUMAN; RHEUMATOID ARTHRITIS; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; CYTOLOGY; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; JUVENILE RHEUMATOID ARTHRITIS; KNOCKOUT MOUSE; METABOLISM; NORMAL HUMAN; PRIMARY CELL CULTURE; SECRETION (PROCESS); SYNOVIAL FLUID;

ADULT; ANIMALS; APTAMERS, NUCLEOTIDE; ARTHRITIS, JUVENILE; CHEMOTACTIC FACTORS; CHROMOSOMAL PROTEINS, NON-HISTONE; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; EXTRACELLULAR TRAPS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; ONCOGENE PROTEINS; POLY-ADP-RIBOSE BINDING PROTEINS; PRIMARY CELL CULTURE; SYNOVIAL FLUID; ZYMOSAN;

EID: 85011876562     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14252     Document Type: Article

References (41)

1. Daikh, D. I. & St Clair, E. W. Updated recommendations for the treatment of rheumatoid arthritis: Another step on a long road. Arthritis care res. 64, 648-651 (2012).
2. Zhou, J. & Rossi, J. J. Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. Mol. Ther. Nucleic acids 3, e169 (2014).
3. Ng, E. W. & Adamis, A. P. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann. NY Acad. Sci. 1082, 151-171 (2006).
4. Ng, E. W. et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5, 123-132 (2006).
5. Mor-Vaknin, N. et al. DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. Arthritis Rheum. 63, 556-567 (2011).
6. Mor-Vaknin, N. et al. The DEK nuclear autoantigen is a secreted chemotactic factor. Mol. Cell Biol. 26, 9484-9496 (2006).
7. Kappes, F. et al. The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes Dev. 25, 673-678 (2011).
8. Saha, A. K. et al. Intercellular trafficking of the nuclear oncoprotein DEK. Proc. Natl Acad. Sci. USA 110, 6847-6852 (2013).
9. Dong, X. et al. Autoantibodies to DEK oncoprotein in a patient with systemic lupus erythematosus and sarcoidosis. Arthritis Rheum. 41, 1505-1510 (1998).
10. Dong, X. et al. Autoantibodies to DEK oncoprotein in human inflammatory disease. Arthritis Rheum. 43, 85-93 (2000).
11. Szer, W., Sierakowska, H. & Szer, I. S. Antinuclear antibody profile in juvenile rheumatoid arthritis. J. Rheumatol. 18, 401-408 (1991).
12. Szer, I. S., Sierakowska, H. & Szer, W. A novel autoantibody to the putative oncoprotein DEK in pauciarticular onset juvenile rheumatoid arthritis. J. Rheumatol. 21, 2136-2142 (1994).
13. Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532-1535 (2004).
14. Villanueva, E. et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187, 538-552 (2011).
15. Khandpur, R. et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci. Transl. Med. 5, 178ra140 (2013).
16. Di Carlo, F. J. & Fiore, J. V. On the composition of zymosan. Science 127, 756-757 (1958).
17. Frasnelli, M. E., Tarussio, D., Chobaz-Peclat, V., Busso, N. & So, A. TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res. Ther. 7, R370-R379 (2005).
18. Koleva, R. I. et al. C/EBPalpha and DEK coordinately regulate myeloid differentiation. Blood 119, 4878-4888 (2012).
19. Warnatsch, A., Ioannou, M., Wang, Q. & Papayannopoulos, V. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 349, 316-320 (2015).
20. Kaplan, M. J. & Radic, M. Neutrophil extracellular traps: double-edged swords of innate immunity. J. Immunol. 189, 2689-2695 (2012).
21. Vossenaar, E. R. et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann. Rheum. Dis. 63, 373-381 (2004).
22. Olszowy, P., Donnelly, M. R., Lee, C. & Ciborowski, P. Profiling posttranslational modifications of histones in human monocyte-derived macrophages. Proteomescience 13, 24 (2015).
23. Sierakowska, H., Williams, K. R., Szer, I. S. & Szer, W. The putative oncoprotein DEK, part of a chimera protein associated with acute myeloid leukaemia, is an autoantigen in juvenile rheumatoid arthritis. Clin. Exp. Immunol. 94, 435-439 (1993).
24. Brinkmann, V. & Zychlinsky, A. Neutrophil extracellular traps: is immunity the second function of chromatinJ. Cell. Biol. 198, 773-783 (2012).
25. Murray, K. J. et al. Antibodies to the 45 kDa DEK nuclear antigen in pauciarticular onset juvenile rheumatoid arthritis and iridocyclitis: selective association with MHC gene. J. Rheumatol. 24, 560-567 (1997).
26. Kappes, F. et al. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol. Cell Biol. 28, 3245-3257 (2008).
27. Nash, P. T. & Florin, T. H. Tumour necrosis factor inhibitors. Med. J. Aust. 183, 205-208 (2005).
28. Lovell, D. J., Bowyer, S. L. & Solinger, A. M. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 52, 1283-1286 (2005).
29. Hakkim, A. et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl Acad. Sci. USA 107, 9813-9818 (2010).
30. Keshari, R. S. et al. Cytokines induced neutrophil extracellular traps formation: implication for the inflammatory disease condition. PLoS One 7, e48111 (2012).
31. Huang, H. et al. Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology 62, 600-614 (2015).
32. Schauer, C. et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat. Med. 20, 511-517 (2014).
33. Keefe, A. D., Pai, S. & Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9, 537-550 (2010).
34. Woods, J. M. et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J. Immunol. 166, 1214-1222 (2001).
35. Nimjee, S. M., Rusconi, C. P. & Sullenger, B. A. Aptamers: An emerging class of therapeutics. Annu. Rev. Med. 56, 555-583 (2005).
36. Que-Gewirth, N. S. & Sullenger, B. A. Gene therapy progress and prospects: RNA aptamers. Gene ther. 14, 283-291 (2007).
37. Kappes, F. et al. Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. Mol. Cell Biol. 24, 6011-6020 (2004).
38. Zhang, M., Berndt, B. E., Chen, J. J. & Kao, J. Y. Expression of a soluble TGFbeta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy. J. Immunol. 181, 3690-3697 (2008).
39. Serezani, C. H., Aronoff, D. M., Jancar, S., Mancuso, P. & Peters-Golden, M. Leukotrienes enhance the bactericidal activity of alveolar macrophages against Klebsiella pneumoniae through the activation of NADPH oxidase. Blood 106, 1067-1075 (2005).
40. Mor-Vaknin, N. et al. Murine colitis is mediated by vimentin. Sci. Rep. 3, 1045 (2013).
41. Ruth, J. H. et al. Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis. Arthritis Res. Ther. 12, R118 (2010).